App-Quantinova.ai

A Composite Score Summarizing Use And Dosing Of Evidence-based Medical Therapies In Heart Failure: Application To The DAPA-HF Trial

Pooja Dewan - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Dapagliflozin

Post-Mortem Study of the Cause of Excess Mortality in Patients with Atrial Fibrillation and Heart Failure

Otilia Tica - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Use of a Self-Care Mobile Phone Application Can Improve Patient Education and Medication Adherence in Patients With Acute Decompensated Heart Failure

Hani essa - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute decompensated heart failure

N/A

Cost-Effectiveness of Earlier Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With a History of Heart Failure

Robert Miller - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Dapagliflozin

The Effect of Dapagliflozin on Serum Uric Acid in Heart Failure With Reduced Ejection Fraction: Insights From DAPA-HF

Kieran F Docherty - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Dapagliflozin

Long Term Outcomes of Ambulatory Outpatient Management of Acute Decompensated Heart Failure in a Heart Failure Specialist Nurse Delivered Consultant Led Unit versus Inpatient Management

Thomas Salmon - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute decompensated heart failure

N/A

Iron Deficiency in Heart Failure is Associated With Upregulation of Pathways Also Related to Cancer Development

Niels Grote Beverborg - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congestive heart failure

N/A

Use of a Novel Cardiac Implantable Electronic Device Digital Care Pathway (TriageHF-Plus) is Associated With a Reduction in All-Cause Unplanned Hospitalizations

Fozia Z Ahmed - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study

Niklas Johansen - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Low Penetrance Sarcomere Variants Indicate an Additive Genetic Risk Model in Hypertrophic Cardiomyopathy

Eric Smith - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Longitudinal Changes in Clinical and Imaging Variables During Withdrawal of Heart Failure Therapy in Patients with Recovered Dilated Cardiomyopathy: An Analysis from TRED-HF

Brian P Halliday - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

David D Berg - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Dapagliflozin

Design of Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction (REALIZE-K Trial)

Mikhail Kosiborod - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Heart failure with reduced ejection fraction

Sodium zirconium cyclosilicate

Physical Activity in Individuals With Hypertrophic Cardiomyopathy: Baseline Data From the Prospective "Lifestyle and Exercise in Hcm" (live-hcm) Study

Rachel Lampert - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Concerns About the Use of Digoxin in Acute Coronary Syndromes

Edina Cenko - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

Digoxin

Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response

Lisa E Emmens - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

furosemide GR

Diagnostic Tests Used to Identify Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the United States

Sarah Brown - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Transthyretin cardiac amyloidosis

N/A

Neuromodulation Of The Renal Nerves In Spontaneously Hypertensive Rats

Ibrahim M Salman - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Pentobarbital

Efficacy of Mavacamten in Patients with Symptomatic Hypertrophic Cardiomyopathy: Sub-Group Analyses by Background Beta-Blocker Use from the EXPLORER-HCM and MAVA-LTE Studies

Daniel L Jacoby - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

MYK 461

The Impact of Hypertension on Disease Expression in Hypertrophic Cardiomyopathy

Thomas M Roston - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypertrophic cardiomyopathy

N/A

Filters

45280 Abstracts